Compliance with good manufacturing practice (“GMP”) is mandatory for all medicinal products that have been granted a marketing authorisation. Likewise, the manufacture of investigational medicinal products must be in accordance with GMP. Advanced therapy medicinal products that are administered to patients under Article 3 of Directive 2001/83/EC (so called “hospital exemption”) must be manufactured under equivalent quality standards to the manufacturing of advanced therapy medicinal products with a marketing authorisation.
Article 5 of Regulation (EC) No 1394/2007 mandates the Commission to draw up guidelines on good manufacturing practice specific to advanced therapy medicinal products ("ATMPs"). Article 63(1) of Regulation (EU) No 536/2014 also empowers the Commission to adopt and publish detailed guidelines on good manufacturing practice applicable to investigational medicinal products.
EC 22.11.2017
EudraLex 22.11.2017
ID 8770 | Last Update 26.08.2026
The International Agency for Research on Cancer just released a new list of classification. I...
This document intends to provide guidance on the implementation of Regulation (EC) No. 648/2004 of the European Parliament and of the Counc...
ID 6592 | Scheda 28.07.2018
Allegato Documento completo con Tabelle operatori economici, ruoli e loro obblighi in relazione alla DdC, ...
Testata editoriale iscritta al n. 22/2024 del registro periodici della cancelleria del Tribunale di Perugia in data 19.11.2024
